The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders ii: Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 2, 2011, Pages 251-270

  da Rocha, Miguel Divino ^a   dias Viegas, Flávia Pereira ^a   Campos, Helineide Cristina ^a   Nicastro, Patrícia Carolina ^a   Fossaluzza, Poliana Calve ^a   Fraga, Carlos Alberto Manssour ^b   Barreiro, Eliezer J ^b   Viegas Jr , Claudio ^a  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alzheimer's disease; Biodiversity; Drug discovery; Medicinal chemistry; Natural products; Neurodegenerative disorders; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN; ASIATIC ACID; ASIATICOSIDE; BRAHMIC ACID; CELASTRUS PANICULATUS EXTRACT; CHOLINESTERASE INHIBITOR; COPTIS CHINENSIS EXTRACT; CROCUS SATIVUS EXTRACT; CURCUMA LONGA EXTRACT; CURCUMIN; CYTOKINE; DOCOSAHEXAENOIC ACID; EVODIA FRUIT EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GINSENOSIDE RB 1; GINSENOSIDE RG 1; GINSENOSIDE RG 3; MAGNOLIA OFFICINALIS EXTRACT; NATURAL PRODUCT; NEW DRUG; PICRORHIZA KURROA EXTRACT; PLANT EXTRACT; RESVERATROL; SALVIA MILTIORRHIZA EXTRACT; SINAPIC ACID; TAU PROTEIN; TENUIFOLISIDE B; TENUIGENIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN PROTECTION; CENTELLA ASIATICA; CENTENELLA ASIATICA; CHINESE MEDICINE; CHOLINESTERASE INHIBITION; COGNITION; COGNITIVE DEFECT; COPTIS; CROCUS; CURCUMA LONGA; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEMENTIA; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; EVODIA; GALANTHUS; GINKGO BILOBA; GINSENG; HERBAL MEDICINE; HIPPOCAMPUS; HUMAN; HUPERZIA; LYCORIS; MAGNOLIACEAE; MEDICINAL PLANT; MEMORY; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PICRORHIZA KURROA; POLYGALACEAE; SALVIA; SALVIA MILTIORRHIZA; SANGUISORBA; STRUCTURE ACTIVITY RELATION; SYMPTOM; TRADITIONAL MEDICINE; TREATMENT OUTCOME; VERATRUM;

EID: 79551671732     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794480429     Document Type: Article

References (280)

1. Campos, H.C.; Rocha, M.D.; Viegas, F.P.D.; Nicastro, P.C.; Fossaluzza, P.C.; Fraga, C.A.M.; Barreiro, E.J.; Viegas-Jr., C. The Role of natural products In the discovery of new drug candidates for the treatment of neurodegenative disorders I: Parkinson's Disease. CNS Neurol. Dis. Drug Targets, 2010, 10(2), 240-251.
2. Viegas-Jr., C.; Bolzani, V.S.; Furlan, M.; Fraga, C.A.M.; Barreiro, E.J. Produtos naturais como candidatos a fármacos úteis no tratamento do Mal de Alzheimer. Quím. Nova, 2004, 27(4), 655-660.
3. Viegas-Jr., C.; Bolzani, V.S.; Barreiro, E.J.; Fraga, C.A.M. New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini Rev. Med. Chem., 2005, 5, 915-926.
4. Standaert, D.G.; Young, A.H. Treatment of central nervous system degenerative disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics; 9th ed., McGraw Hill: New York, 1996, pp. 503-519.
5. Arnold, S.E.; Hyman, B.T.; Flory, J.; Damasio, A.R.; Van Hoesen, G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex, 1991, 1, 103-116.
6. Olney, J.W. Brain lesions, obesity, and other disturbances in mice related with monosodium glutamate. Science 1969, 164, 719-721.
7. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med., 1994, 330, 613-622.
8. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science, 1992, 256, 628-632.
9. Schapira, A.H.; Mann, V.M.; Cooper, J.M.; Dexter, D.; Daniel, S.E.; Jenner, P.; Clark, J.B.; Marsden, C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem., 1990, 55, 2142-2145.
10. McKeel, D.W.; Jr. Price, J.L.; Miller, J.P.; Grant, E.A.; Xiong, C.; Berg, L. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J. Neuropathol. Exp. Neurol., 2004, 63, 1028-1037.
11. Alzheimer's Association. 2009 Alzheimer's Disease Facts and Figures Available at: www.alz.org [Accessed February 2010].
12. Delagarza, V.W. Pharmacologic treatment of Alzheimer's disease: An update. Am. Family Phys., 2003, 7, 1365-1372.
13. Small, G.W.; Rabins, P.V.; Barry, P.P.; Buckholtz, N.S.; DeKosky, S.T.; Ferris, S.H.; Finkel, S.I.; Gwyther, L.P.; Khachaturian, Z.S.; Lebowitz, B.D.; McRae, T.D.; Morris, J.C.; Oakley, F.; Schneider, L.S.; Streim, J.E.; Sunderland, T.; Teri, L.A.; Tune, L.E. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA, 1997, 278, 1363-1371.
14. Sun, A.Y.; Wang, Q.; Simonyi, A.; Sun, G.Y. Botanical phenolics and brain health sNeuromol. Med., 2008, 10, 259-274.
15. Masters C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA, 1985, 82, 4245-4249.
16. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 1984, 120, 885-890.
17. Michaelis, M.L. Drugs targeting Alzheimer's disease: Some things old and some things new. J. Pharmacol. Exp. Ther., 2003, 304, 897-904.
18. Zhu, X.; Lee, H.; Perry, G.; Smith, M.A. Alzheimer disease, the two-hit hypothesis: An update. Biochim. Biophys. Acta, 2007, 1772, 494-502.
19. Butterfield, D.A.; Griffin, S.; Munch, G.; Pasinetti, G.M. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimer Dis., 2002, 4, 193-201.
20. Selkoe, D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimer Dis., 2001, 3, 75-80.
21. Snyder, E.M.; Nong, Y.; Almeida, C.G.; Paul, S.; Moran, T.; Choi, E.Y.; Nairn, A.C.; Salter, M.W.; Lombroso, P.J.; Gorras, G.K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 2005, 8, 1051-1058.
22. Kishida, K.T.; Pao, M.; Holland, S.M.; Klann, E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J. Neurochem., 2005, 94, 299-306.
23. Kishida, K.T.; Klann, E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid. Redox Signal., 2007, 9, 233-244.
24. Shelat, P.B.; Chalimoniuk, M.; Wang, J.H.; Strosznajder, J.B.; Lee, J.C.; Sun, A.Y.; Simonyi, A.; Sun, G.Y. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J. Neurochem., 2008, 106, 45-55.
25. Clemens, J.A.; Stephenson, D.T.; Smalstig, E.B.; Roberts, E.F.; Johnstone, E.M.; Sharp, J.D.; Little, S.P.; Kramer, R.M. Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Stroke, 1996, 27, 527-535.
26. Newton, R.; Kuitert, L.M.; Slater, D.M.; Adcock, I.M.; Barnes, P.J. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epitelial cells. Life Sci., 1997, 60, 67-78.
27. Dennis, E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem., Sci. 1997, 22, 1-2.
28. Tischfield, J.A. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J. Biol. Chem., 1997, 272, 17247-17250.
29. Clark, J.D.; Lin, L.L.; Kriz, R.W.; Ramesha, C.S.; Sultzman, L.A.; Lin, A.Y.; Milona, N.; Knopf, J.L. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell, 1991, 65, 1043-1051.
30. Glover, S.; de Carvalho, M.S.; Bayburt, T.; Jonas, M.; Chi, E.; Leslie, C.C.; Gelb, M.H. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J. Biol. Chem., 1995, 270, 15359-15367.
31. Morita, I.; Schindler, M.; Reiger, M.K.; Otto, J.C.; Hori, T.; DeWitt, D.L.; Smith, W.L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem., 1995, 270, 10902-10908.
32. Sang, N.; Chen, C. Lipid signaling and synaptic plasticity. Neuroscientist, 2006, 12, 425-434.
33. Lin, L.L.; Wartmann, M.; Lin, A.Y.; Knopf, J.L.; Seth, A.; Davis, R.J. Cpla2 is phosphorylated and activated by MAP kinase. Cell, 1993, 72, 269-278.
34. Kriem, B.; Sponne, I.; Fifre, A. Malaplate-Armand, C.; Lozac'h-Pillot, K.; Koziel, V.; Yen-Potin, F.T.; Bihain, B.; Oster, T.; Olivier, J-L.; Pillot, T. Cytolosic phospholipase A2 mediates neuronal apoptosis induyced by soluble oligomers of the amyloid-beta peptide. FASEB J., 2005, 19, 85-87.
35. Abramov, A.Y.; Canevari, L.; Duchen, M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci., 2004, 24, 565-575.
36. Paris, D.; Town, T.; Mullan, M. Novel strategies for opposing murine microglial activation. Neurosci.Lett. 2000, 278, 5-8.
37. Faroqui, A.A.;Rapoport, S.I.; Horrocks, L.A. Membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res., 1997, 22, 523-527.
38. Nitsch, R.M.; Blusztajn, J.K.; Pittas, A.G.; Slack, B.E.; Growdon, J.H.; Wurtman, R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA, 1992, 89, 1671-1675.
39. Iwamoto, N.; Kobayashi, K.; Kosaka, K. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimertype dementia patients. J. Neurol., 1989, 236, 80-84.
40. Jeandel, C.; Nicolas, M.B.; Dubois, F.; Nabet-Belloville, F.; Penin, F.; Curry, G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology, 1989, 35, 275-282.
41. Thomas, T.; Thomas, G.; Mclendon, C.; Sutton, T.; Mullan, M. Beta amyloid-mediated vasoactivity and vascular endothelial damage. Nature, 1996, 380, 168-171.
42. Crawford, F.; Suo, Z.; Fang, C.; Mullan, M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol., 1998, 150, 159-168.
43. Paris, D.; Parker, T.A.; Town, T.; Suo, Z.; Fang, C.; Humphrey, J.; Crawford, F.; Mullan, M. Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's β-amyloid1-40 peptide. Exp. Neurol., 1998, 152, 116-122.
44. Paris, D.; Town, T.; Mori, T.; Parker, T.A.; Humphrey, J.; Mullan, M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging, 2000, 21, 183-197.
45. Davies, P.; Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 1976, 2, 1403.
46. Bowen, D.M.; Smith, C.B.; White, P.; Davison, A.N. Neurotransmitterrelated enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 1976, 99, 459-496.
47. Perry, E.K.; Gibson, P.H.; Blessed, G.; Perry, R.H.; Tomlinson, B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci., 1977, 34, 247-265.
48. Hardy J. A hundred years of Alzheimer's disease research. Neuron, 2006, 52, 3-13.
49. Clinical Trials for Alzheimer's disease.http://www.ahaf.org/alzheimers/treatment/clinicaltrials.html. Accessed february 2010.
50. http://www.alzheimers.org/clinicaltrials. Acessed February 2010.
51. http://www.newmeds.phrma.org. Accessed February 2010.
52. http://www.clinicaltrials.org. Acessed February 2010.
53. http://www.alz.org. Accessed February 2010.
54. http://www.search.cochrane.org. Accessed February 2010.
55. http://www.alzforum.org. Accessed February 2010.
56. Kim, S.; Ahn, K.; Oh, T.H.; Nah, S.Y.; Rhim, H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem. Biophys. Res. Commun., 2002, 296, 247-254.
57. Kim, S.; Kim, T.; Ahn, K.; Park, W.K.; Nah, S.Y.; Rhim, H. Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons. Biochem. Biophys. Res. Commun., 2004, 323, 416-424.
58. Karikura, M.; Miyase, T.; Tanizawa, H.; Taniyama, T.; Takino, Y. Studies on absorption, distribution, excretion and metabolism of ginseng saponins.VII. Comparison of the decomposition modes of ginsenoside-Rb1 and -Rb2 in the digestive tract of rats. Chem. Pharm. Bull., 1991, 39, 2357-2361.
59. Bae, E.A.; Han, M.J.; Choo, M.K.; Park, S.Y.; Kim, D.H. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull., 2002, 25, 58-63.
60. Akao, T. Kanaoka, M.; Kabashi, K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay. Biol. Pharm. Bull., 1998, 21, 245-249.
61. Park, E.K.; Choo, M.K.; Oh, J.K.; Ryu, J.H.; Kim, D.H. Ginsenoside Rh2 reduces ischemic brain injury in rats. Biol. Pharm. Bull., 2004, 27, 433-436.
62. Jeong, S.M.; Lee, J.H.; Kim, J.H.; Lee, B.H.; Yoon, I.S.; Kim, D.H.; Rhim, H.; Kim, Y.; Nah, S.Y. Stereospecificity of ginsenoside Rg3 action on ion channels. Mol. Cells, 2004, 18, 383-389.
63. Kang, D.I.; Lee, J.Y.; Yang, J.Y.; Jeong, S.M.; Lee, J.H.; Nah, S.Y.; Kim, Y. Evidence that the tertiary structure of 20(S)-ginsenoside Rg3 with tight hydrophobic packing near the chiral center is important for Na(+) channel regulation. Biochem. Biophys. Res. Commun., 2005, 333, 1194-1201.
64. Lee, E.; Kim, S.; Chung, K.C.; Choo, M.-K.; Kim, D.-H.; Nam, G.; Rhim, H. 20(S)-ginsenoside Rh2, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons. Eur. J. Pharmacol., 2006, 536, 69-77.
65. Kuryatov, A.; Laube, B.; Betz, H.; Kuhse, J. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron, 1994, 12, 1291-1300.
66. Williams, K.; Kashiwagi, K.; Fukuchi, J.; Igarashi, K. An acidic amino acid in the N-methyl-D-aspartate receptor that is important for spermine stimulation. Mol. Pharmacol., 1995, 48, 1087-1098.
67. Hirai, H.; Kirsch, J.; Laube, B.; Betz, H.; Kuhse, J. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc. Natl. Acad. Sci. USA, 1996, 93, 6031-6036.
68. Howes, M.-J.R.; Houghton, P.J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol. Biochem. Behav., 2003, 75, 513-527.
69. Nalini, K.; Karanth, K.S.; Rao, A.; Aroot, A.R. Effects of Celastrus paniculatus on passive avoidance performance and biogenic amine turnover in albino rats. J. Ethnopharmacol., 1995, 47, 101-108.
70. Kumar, M.H.V.; Gupta, Y.K. Antioxidant property of Celastrus paniculatus Willd.: a possible mechanism in enhancing cognition. Phytomedicine, 2002, 9(4), 302-311.
71. Dev, S. Ethnotherapeutics and modern drug development: the potential of Ayurveda. Curr. Sci., 1997, 73(11), 909-928.
72. Brinkhaus, B.; Lindner, M.; Schuppan, D.; Hahn, E.G. Chemical, pharmacological and clinical profile of the East Asian medicinal plant Centella asiatica. Phytomedicine, 2000, 7(5), 427-448.
73. Asakawa, Y.; Matsuda, R.; Takemoto, T. Monoterpenoids and sesquiterpenoids from Hydrocotyle and Centella species. Phytochemistry, 1982, 21(10), 2590-2592.
74. Miyazawa, M.; Watanabe, H.; Kameoka, H. Inhibition of acetylcholinesterase activity by monoterpenoids with a p-menthane skeleton. J. Agric. Food. Chem., 1997, 45, 677-679.
75. Perry, N.S.L.; Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and onstituent terpenes. J. Pharm. Pharmcol., 2000, 52, 895-902.
76. Ryan, M.F.; Byrne, O. Plant-insect coevolution and inhibition of acetylcholinesterase. J. Chem. Ecol., 1988, 14(10), 1965-1975.51.
77. Sakina, M.R.; Dandiya, P.C. A psycho-neuropharmacological profile of Centella asiática extract. Fitoterapia, 1990, 61(4)̧291-296.
78. Lake, J.T.; Grossberg, G.T. Management of psychosis, agitation, and other behavioural problems in Alzheimer's disease. Psychiatr. Ann., 1987, 17, 371-374.
79. Lebert, F.; Pasquier, F.; Petit, H. Behavioural effects of trazodone in Alzheimer's disease. J. Clin. Psychiatry, 1994, 55(12), 536-538.
80. Simpson, P.M.; Foster, D. Improvement in organically disturbed behavior with trazodone treatment. J. Clin. Psychiatry, 1986, 47, 191-193.
81. Nalini, K.; Aroor, A.R.; Karanth, K.S.; Rao, A. Effect of Centella asiatica fresh leaf aqueous extract on learning and memory and biogenic amine turnover in albino rats. Fitoterapia, 1992, 63(3), 232-237.
82. Inamdar, P.K.; Yeole, R.D.; Ghogare, A.B.; de Souza, N.J. Determination of biologically active constituents in Centella asiatica. J. Chromatogr. A, 1996, 742, 127-130.
83. Lee, M.K.; Kim, S.R.; Sung, S.H.; Lim, D.Y.; Kim, H.; Choi, H.; Park, H.K.; Je, S.; Ki, Y.C. Asiatic acid derivatives protect cultured neurons from glutamate-induced excitotoxity. Res. Comm. Mol. Pathol. Pharmacol., 2000, 108(1-2), 75-86.
84. Barbosa, N.R.; Pitella, F.; Gattaz, W.F. Centella asiática water extract inhibits iPLA2 and cPLA2 activities in rat cerebellum. Phytomedicine, 2008, 15, 896-900.
85. Farooqui, A.A.; Yang, H.C.; Rosemberger, T.A.; Horrocks, L.A. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. J. Neurochem., 1997, 69, 889-901.
86. Murakami, M.; Shimbara, S.; Kambe, T.; Kuwata, H.; Winstead, M.V.; Tischfield, J.A.; Kudo, I. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. J. Biol. Chem., 1998, 23, 14411-14423.
87. Subathra, M.; Shila, S.; Devi, M.A.; Panneerselvam, C. Emerging role of Centella asiatica in improving age-related neurological antioxidants status. Exp. Gerontol., 2005, 40, 707-715.
88. Kim, S.R.; Koo, K.A.; Lee, M.K.; Park, H.G.; Sang-Sup, J.; Cha, K. Kim, Y.C. Asiatic acid derivatives enhance cognitive performance partly by improving acetylcholine synthesis. J. Pharm. Pharmacol., 2004, 56, 1275-1282.
89. Inhee, M.J.; Eun, S.J.; Hwan, Y.S.; Kyoon, H.; Young, K.J.; Keun, P.H.; Sang-Sup, J.; Whan, J.M. Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity. J. Neurosci. Res., 1999, 58, 417-425.
90. Sang-Sup, J.; Chi-Hyoung, Y.; Doo-Yeon, L.; Heenan, K.; Inhee, M.J.; Min, W.J.; Heesung, C.; Young-Hoon, J.; Heedoo, K.; Hyeung-Geun, P. Structure-activity relationship study of Asiatic acid derivatives against beta-amyloid (Aβ)-induced neurotoxicity. Bioorg. Med. Chem.Lett. 2000, 10, 119-121.
91. Das, K.C.; Das, C.K. Curcumin (diferuloylmethane), a singlet oxygen (O-1(2)) quencher. Biochem. Biophys. Res. Commun., 2002, 295(1), 62-66.
92. Miquel, J.; Bernd. A.; Sempere, J.M.; Diaz-Alperi, J.; Ramirez, A. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch. Gerontol. Geriatr., 2002, 34(1), 37-46.
93. Priyadarsini, K.I. Free radical reactions of curcumin in membrane models. Free Radic. Biol. Med., 1997, 23(6), 838-843.
94. Scartezzini, P.; Speroni, E. A review on some plants of Indian traditional medicine with antioxidant activity. J. Ethnopharmacol., 2000, 71(1-2), 23-43.
95. Rajakrishman, V.; Viswanathan, P.; Rajasekharam, K.N.; Menon, V.P. Neuroprotective role of curcumin from Curcuma longa on ethanol-induced brain damage. Phytother. Res., 1999, 13(7), 571-574.
96. Khanna, S.; Park, H-A.; Sen, C.K.; Golakoti, T.; Sengupta, K.; Venkateswarlu, S.; Roy, S. Neuroprotective and antiinflammatory properties of a novel demethylated curcuminoid. Antioxid. Redox Signal., 2009, 11(3), 449-468.
97. Chan, M.M.Y.; Huang, H.I.; Fenton, M.R.; Fong, D. In vivo inhibition of nitric oxide synthase gene expression by curcumin in gene expression by curcumin, an cancer prevention natural product with anti-inflammatory properties. Biochem. Pharmacol., 1998, 55, 1955.
98. Hasegawa, K.; Naiki, M.; Yamada, J. Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuroscience, 2004, 75, 742-750.
99. Rajeswari, A.; Sabesan, M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology, 2008, 16, 96-99.
100. Kim, D.S.H.L.; Kim, J.Y. Total synthesis of calebin-A, preparation of its analogues, and their neuronal cell protective against β-amyloid insult. Biooorg. Med. Chem.Lett. 2001, 11(18), 2541-2543.
101. Park, S.Y.; Kim, D.S.H.L. Discovery of natural products from curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J. Nat. Prod., 2002, 65(9), 1227-1231.
102. Kim, D.S.H.L.; Park, S.Y.; Kim, J.Y. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci.Lett. 2001, 303(1), 57-61.
103. Ramsewak, R.S.; DeWitt, D.L.; Nair, M.G. Citotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine, 2000, 7(4), 303-308.
104. Skrzypczak-Jankun, E.; McCabe, N.P.; Selman, S.H.; Jankun, J. Curcumin inhibits lipoxigenase by binding to its central cavity: theoretical and X-ray evidence. Int. J. Mol. Med., 2000, 6(5), 521-526.
105. Srivastava, K.C.; Bordia, A.; Verma, S.K. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanooid metabolism in human blood platelets. Prostaglandines Leukot. Essent. Fatty Acids, 1995, 52(4), 223-227.
106. Yu, Z.F.; Kong, L.D.; Chen, Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J. Ethnopharmacol., 2002, 83(1-2), 161-165.
107. Frautschy, S.A.; Hu, W.; Kim, P.; Miller, S.A.; Chu, T.; Harris-White, M.E.; Cole, G.M. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging, 2001, 22, 993-1005.
108. Lim, H.J.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. Curcumin reduces Alzheimer pathology in APP transgenics. J. Neurosci., 2001, 21, 8370-8377.
109. Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L. A Potential role of the curry spice Curcumin in Alzheimer's disease. Curr. Alzheimer Res., 2005, 2, 131-136.
110. Maurer, K.; Ihl, R.; Dierks, T.; Frölich, L. Clinical efficacy of Ginkgo biloba extract EGb 761 in dementia of the Alzheimer type. J. Psychiatr. Res., 1997, 31(6), 645-655.
111. Heiss, W.D.; Zeiler, K. Drug influence on cerebral circulation. Pharmakoterapie, 1978, 1, 137-144.
112. Loffler, T.; Lee, S.K.; Noldner, M.; Chatterjee, S.S.; Hoyer, S.; Schliebs, R. Effect of Ginkgo biloba extract (EBg 761) on glucose metabolism-related markers in streptozotocin-damaged rat brain. J. Neural Transm., 2001, 108(12), 1457-1474.
113. Tea, S.; Celsis, P.; Clanet, M.; Marc-Vergnes, J-P.; Boeters, U. Quantified parameters for the proof of the enhancement of cerebral circulation and metabolism. Therapiewoche, 1987, 37, 2655-2657.
114. Kristofiková, Z.; Benesová, O.; Tejkalová, H. Changes of highaffinity choline uptake in the hippocampus of old rats after longterm administration of two nootropic drugs (tacrine and Ginkgo biloba extract). Dementia, 1992, 3, 304-307.
115. Barth, S.A.; Inselmann, G.; Engemann, R.; Heidemann, H.T. Influences of Ginkgo biloba on cyclosporine A induced lipid peroxidation in human liver microsomes in comparisom to vitamin E, glutathione and N-acetylcysteine. Biochem. Pharmacol., 1991, 41, 1521-1526.
116. Marcocci, L.; Packer, L.; Droy-Lefaix, M-T.; Sekaki, A.; Gardès-Albert, M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol., 1994, 234, 462-475.
117. Topic, B.; Tani, E.; Tsiakitzis, K.; Kourounakis, P.N.; Dere, E.; Hasenöhrl, R.U.; Häcker, R.; Mattern, C.M.; Huston, J.P. Enhanced maze performance and reduced oxidative stress by combined extracts of Zinziber officinale and Ginkgo biloba in the aged rat. Neurobiol. Aging, 2002, 23(1), 135-143.
118. Bastianetto, S.; Ramassamy, C.; Dore, S.; Christen, Y.; Poirier, J.; Quirion, R. The Ginkgo biloba extract (Egb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur. J. Neurosci., 2000, 12(6), 1882-1890.
119. Bastianetto, S.; Zheng, W.H.; Quirion, R. The Ginkgo biloba extract (Egb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: Involvement of its flavonoid constituents and protein kinase C. J. Neurochem., 2000, 74(6), 2268-2277.
120. Schindowski, K.; Leutner, S.; Kressmann, S.; Eckert, A.; Muller, W.E. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb 761). J. Neural Transm., 2001, 108(8-9), 969-978.
121. Yao, Z.; Drieu, K.; Papadopoulos, V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands. Brain Res., 2001, 889(1-2), 181-190.
122. Chandrasekaran, K.; Mehrabian, Z.; Spinnewyn, B.; Drieu, K. Kiskum, G. Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res., 2001, 922, 282-292.
123. Rapin, J.R.; Zaibi, M.; Drieu, K. In vitro and in vivo effects of an extract of Ginkgo biloba (EGb 761), ginkgolide B, and bilobalide on apoptosis in primary cultures of rat hippocampal neurons. Drug Rev. Res., 1998, 45, 23-29.
124. Seif-El-Nasr, M.; El-Fattah, A.A. Lipid peroxide, phospholipids, glutathione levels and superoxide dismutase activity in rat brain after ischaemia: effect of Ginkgo biloba extract. Pharmacol. Res., 1995, 32, 273-278.
125. Pietri, S.; Maurelli, E.; Drieu, K.; Culcasi, M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J. Mol. Cell. Cardiol., 1997, 29, 733-742.
126. Chopin, P.; Briley, M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psycopharmacology, 1992, 106, 26-30.
127. Petkov, V.D.; Kehayov, R.; Belcheva, S.; Kontantinova, E.; Petrov, V.V.; Getova, D.; Markovska, V. Memory effects of standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK501) and their combination Ginkosan (PHL-00701). Planta Med., 1993, 59,106-114.
128. Stoll, S.; Scheuer, K.; Pohl, O.; Müller, W.E. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the ageing mouse. Pharmacopsychiatry, 1996, 29, 144-149.
129. Hofferberth, B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type: a double-blind, placebo-controlled study on different levels of investigation. Hum. Psychopharmacol., 1994, 9, 215-222.
130. Kanowski, S.; Hermann, W.M.; Stephan, K.; Wierch, W.; Hörr, R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Phytomedicine, 1997, 4(1), 3-13.
131. Le Bars, P.L.; Katz, M.M.; Berman, N.; Itil, T.M.; Freedman, A.M.; Schatzberg, A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. J.Am. Med. Assoc., 1997, 278(16), 1327-1332.
132. Le Bars, P.L.; Kieser, M.; Itil, K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord., 2000, 11(4), 230-237.
133. Le Bars, P.L.; Velasco, F.M.; Ferguson, J.M.; Dessain, E.C.; Kieser, M.; Hoerr, R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 ((R)) in Alzheimer's disease. Neuropsychobiology, 2002, 45(1), 19-26.
134. Oken, B.S.; Storzbach, D.M.; Kaye, J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol., 1998, 55, 1409-1415.
135. Rai, G.S.; Shovlin, C.; Wesnes, K.A. A double-blind, placebo controlled study of Ginkgo biloba extract (Tanakan) in elderly outpatients with mild to moderate memory impairment. Curr. Med. Res. Opin., 1991, 12(6), 350-355.
136. Rigney, U.; Kimber, S.; Hindmarch, I. The effects of acute doses of stardardised Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother. Res., 1999, 13, 408-415.
137. Kubota, Y.; Tanaka, N.; Umegaki, K.; Takenaka, H.; Mizuno, H.; Nakamura, K.; Shinozuka, K.; Kunitomo, M. Ginkgo biloba extract-induced relaxation of rat aorta is associated with increase in endothelial intracellular calcium level. Life Sci., 2001, 69, 2327-2336.
138. Braquet, P.G.; Hosford, D.; Koltai, M.; Ginkgolide B (BN 52021): a natural PAF receptor antagonist. Neuropsychopharmacology, 1994, 10(suppl 3), 693S.
139. Skolnick, A.A. Old herbal Chinese medicine used for fever yields possible new Alzheimer disease therapy. J. Am. Med. Assoc., 1997, 277(10), 776.
140. Wang, Y-E.; Yue, D-X.; Tang, X-C. Anticholinesterase activity of huperzine A. Acta Pharmacol. Sin., 1986, 7(2), 110-113.
141. McKinney, M.; Millar, J.H.; Yamada, F.; Tuckmantel, W.; Kozikowski, A.P. Potencies and stereoselectives of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur. J. Pharmacol., 1991, 203, 303-305.
142. Laganière, S.; Corey, J.; Tang, X-C.; Wülfert, E.; Hanin, I. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology, 1991, 30(7), 763-768.
143. Ashani, Y.; Peggins, J.O.; Doctor, B.P. Mechanism of inhibition of cholinesterases by huperzine A. Biochem. Biophys. Res. Commun., 1992, 184(2), 719-726.
144. Lu, W-H.; Shou, J.; Tang, X-C. Improving effect of huperzine A in aged rats and adults rats with experimental cognitive impairment. Acta Pharmacol. Sin., 1988, 9(1), 11-15.
145. Wang, L.M.; Han, Y.F.; Tang, X.C. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur. J. Pharmacol., 2000, 398(1), 65-72.
146. Zhou, J.; Fu, Y.; Tang, X.C. Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci. Lett. 2001, 306, 53-56.
147. Shu, Y-Z. Recent natural products based drug development: a pharmaceutical industry perspective. J. Nat. Prod., 1998, 61, 1053-1071.
148. Small, G.W.; Rabins, R.V.; Barry, P.P.; Buckholtz, N.S.; DeKosky, S.T.; Ferris, S.H.; Finkel, S.I.; Gwyther, L.P.; Khachaturian, Z.S.; Lebowitz, B.D.; McRae, T.D.; Morris, J.C.; Oakley, F.; Schneider, L.S.; Streim, J.E.; Sunderland, T.; Teri, L.A.; Tune, L.E. Diagnosis and treatment of Alzheimer's disease related disorders. J. Am. Med. Assoc., 1997, 278(16), 1363-1367.
149. Xiao, X.Q.; Zhang, H.Y.; Tang, X.C. Huperzine A attenuates amyloid β-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and capase-3 activation. J. Neurosci. Res., 2002, 67(1), 30-36.
150. Zhou, J.; Zhang, H.Y.; Tang, X.C. Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci.Lett. 2001, 313(3), 137-140.
151. Xiao, X.Q.; Yang, J.W.; Tang, X.C. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci.Lett. 1999, 275, 73-76.
152. Ved, H.S.; Koenig, M.L.; Dave, J.R.; Doctor, B.P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport, 1997, 8(4), 963-968.
153. Wang, X.D.; Zhang, J.M.; Yang, H.H.; Hu, G.Y. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol. Sin., 1999, 20(1), 31-35.
154. Zhou, J.; Tang, X.C. Huperzine A attenuates apoptosis and mitochondria-dependent capase-3 in rat cortical neurons. FEBSLett. 2002, 526, 21-25.
155. Bores, G.M.; Huger, F.P.; Petko, W.; Mutlib, A.E.; Camacho, F.; Rush, D.K.; Selk, D.E.; Wolf, V.; Koley Jr, R.W.; Davis, L.; Vargas, H.M. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther., 1996, 277, 728-738.
156. Wilcock, G.K.; Lilienfeld, S.; Gaens, E. On behalf of the Galanthamine International-1 Study Group. Efficacy and safety of galanthamine in patients with mild to moderate Alzheimer's disease: mulitcentre randomized controlled trial. BMJ, 2000, 321, 1445-1449.
157. Wilkinson, D.; Murray, J. Galanthamine: a randomized, doubleblind, dose comparison in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2001, 16(9), 852-857.
158. Bickel, U.; Thomsen, T.; Weber, W.; Fischer, J.P.; Bachus, R.; Nitz, M. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol., 1991, 50, 420-428.
159. Fulton, B.; Benfield, P. Galanthamine. Drugs Aging, 1996, 1, 60-67.
160. Harvey, A.L. The pharmacology of galanthamine and its analogues. Pharmacol. Ther., 1995, 68(1), 113-128.
161. Pearson, V.E. Galanthamine: a new Alzheimer drug with a past life. Ann. Pharmacother., 2000, 35(11), 1406-1413.
162. Woodruff-Pak, D.S.; Vogel, R.W.; Wenk, G.L. Galanthamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Natl. Acad. Sci. USA, 2001, 98(4), 2089-2094.
163. Irwin, R.L.; Smith, H.J. Cholinesterase inhibition by galanthamine and lycoramine. Biochem. Pharmacol., 1960, 3(2), 147-148.
164. Hou, Y.C.; Chao, P.D.; Chen, S.Y. Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. Am. J. Chin. Med., 2000, 28(3-4), 379-384.
165. Chen, Y.L.; Lin, K.F.; Shiao, M.S.; Chen, Y.T.; Hong, C.Y.; Lin, S.J. Magnolol, a potent antioxidant from Magnolia officinalis, attenuates intimal thickening and MCP-1 expression after balloon injury of the aorta in cholesterol-fed rabbits. Basic Res. Cardiol., 2001, 96(4), 353-363.
166. Kong, C.W.; Tsai, K.; Chin, J.H.; Chan, W.L.; Hong, C.Y. Magnolol attenuates peroxidative damage and improves survival of rats with sepsis. Shock, 2000, 13(1), 24-28.
167. Lo, Y.C.; Teng, C.M.; Chen, C.F.; Chen, C.C.; Hong, C.Y. Magnolol and honokiol from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem. Pharmacol., 1994, 47(3), 549-553.
168. Chiu, J.H.; Ho, C.T.; Wei, Y.H.; Lui, W.Y.; Hong, C.Y. In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury. Life Sci., 1997, 61(19), 1961-1971.
169. Kuribara, H.; Kishi, E.; Hattori, N.; Yuzurihara, M.; Maruyama, Y. Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of Magnolia. Phytother. Res., 1999, 13(7), 593-596.
170. Kuribara, H.; Kishi, E.; Hattori, N.; Okada, M.; Maruyama, Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from Magnolia bark. J. Pharm. Pharmacol., 2000, 52(11), 1425-1429.
171. Squires, R.F.; Ai, J.; Witt, M.R.; Kahnberg, P.; Saederup, E.; Sterner, O.; Nielsen, M. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. Neurochem. Res., 1999, 24(12), 1593-1602.
172. Lee, M.M.; Hseih, M.T.; Kuo, J.S.; Yeh, F.T.; Huang, H.M. Magnolol protects cortical neuronal cells from chemical hypoxia in rats. Neuroreport, 1998, 9(15), 3451-3456.
173. Wang, J.P.; Hsu, M.F.; Raung, S.L.; Chen, C.C.; Kuo, J.S.; Teng, C.M. Anti-inflammatory and analgesic effects of magnolol. Naunyn Schmiedebergs Arch. Pharamcol., 1992, 346(6), 707-712.
174. Wang, J.P.; Ho, T.F.; Chang, L.C.; Chen, C.C. Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A23187-induced pleurisy in mice. J. Pharm. Pharamacol., 1995, 47(10), 857-860.
175. Jia, H.; Jiang, Y.; Ruan, Y.; Zhang, Y.; Ma, X.; Zhang, J.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid β-protein in cultured cells. Neurosci.Lett. 2004, 367, 123-128.
176. Park, C.H.; Choi, S.H.; Koo, J-W.; Seo, J-H.; Kim, H-S.; Jeong, SJ.; Suh, Y-H. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11. J. Neurosci. Res., 2002, 70, 484-492.
177. Yabe, T.; Iizuka, S.; Komatsu, Y.; Yamada, H. Enhancements of choline acetyltransferase activity and nerve growth factor secretion by Polygalae Radix-extract containing active ingredients in Kamiutam-to. Phytomedicine, 1997, 4(3), 199-205.
178. Yamada, H.; Yabe, T. Anti-dementia actions of Kampo (Japaneseherbal) medicines effects of Kampo medicines on central nervous system. Curr. Top. Phytochem., 1997, 1, 157-168.
179. Ikeya, Y.; Shigefumi, T.; Tunakawa, M.; Karakida, H.; Toda, K.; Yamaguchi, T.; Aburada, M. Cognitive improving and cerebral protective effects of acylated oligosaccharides in Polygala tenuifolia. Biol. Pharm. Bull., 2004, 27(7), 1081-1085.
180. Karakida, F.; Ikeya, Y.; Tsunakawa, M.; Yamaguchi, T.; Ikarashi, Y.; Takeda, S.; Aburada, M. Cerebral protective and cognitionimproving effects of sinapic acid in rodents. Biol. Pharm. Bull., 2007, 30(3), 514-519.
181. Perry, N.S.L.; Bollen, C.; Perry, E.K.; Ballard, C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol. Biochem. Behav., 2003, 75, 651-659.
182. Perry, N.S.L.; Houghton, P.J.; Sampson, J.; Theobald, A.E.; Hart, S.; Lis-Balchin, M.; Hoult, J.R.; Evans, P.; Jenner, P.; Milligan, S.; Perry, E.K. In vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J. Pharm. Pharmacol., 2001, 53, 1347-1356.
183. Adam, J.N.; Sivropoulou, A.; Kokkini, S.; Lanaras, T.; Arsenakis, M. Antifungal activities of Origarnum vulgare subsp. Hyrtum, Mentah spicata, Lavandula angustifólia and Salvia fruticose essencial oils against human pathogenic fungi. J. Agric. Food. Chem., 1998, 46, 1739-1745.
184. Dorman, H.J.P.; Deans, S.G.; Noble, R.C. Evaluation in vitro of plant essential oils as natural antioxidants. J. Essent. Oil Res., 1995, 7, 645-651.
185. Lu, Y.; Foo, L.Y. Antioxidant activities of polyphenols from sage (Salvia officinalis). Food Chem., 2001, 75, 197-202.
186. Malencic, D.J.; Gasic, O.; Popovic, M.; Boza, P. Screening for antioxidant properties of Salvia reflexa Hornem. Phytother. Res., 2000, 14, 546-548.
187. Zupko, I.; Hohmann, J.; Redei, D.; Falkay, G.; Janicsak, G.; Mathe, I. Antioxidant activity of leaves of Salvia species in enzymedependent and enzyme-independent systems of lipid peroxidation and their phenolic constituents. Planta Med., 2001, 67, 366-368.
188. Howes, M-JR.; Perry, N.S.L.; Houghton, P.J. Plants with traditional uses and activities relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res., 2003, 17(1), 1-18.
189. Maklad, Y.A.; Aboutabi, E.A.; El-Sherei, M.M.; Meselhy, K.M. Bioactivity studies of Salvia transsylvannica (Schur ex Griseb) grown in Egypt. Phytother. Res., 1999, 13, 147-150.
190. Zandi, P.P.; Breitner, J.C.S. Do NSAIDs prevent Alzheimer's disease? And, If so, Why? The epidemiological evidence. Neurobiol. Aging, 2001, 22, 811-817.
191. Perry, N.S.L.; Houghton, P.J.; Jenner, P.; Keith, A.; Perry, E.K. Salvia lavandulaefoila essential oil inhibits cholinesterase in vivo. Phytomedicine, 2002, 9(1), 48-51.
192. Perry, N.S.L.; Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. In vitro: inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituents terpenes. J. Pharm. Pharmacol., 2000, 8, 895-902.
193. Savelev, S.; Okello, E.; Perry, N.S.L.; Wilkins, R.M.; Perry, E.K. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol. Biochem. Behav., 2003, 75, 661-668.
194. Kuang, P.; Wu, W.; Liu, J.; Zhang, F.; Pu, C. The effect of Radix Salviae Miltiorrhizae (RSM) on substance P in cerebral ischemia-animal experiment. J. Trad. Chin. Med., 1991, 11(2), 123-127.
195. Kuang, P.; Tao, Y.; Tian Y. Effect of Radix Salviae Miltiorrhizae on nitric oxide in cerebral ischemic-reperfusion injury. J. Trad. Chin. Med., 1996, 16(3), 224-227.
196. Kuang, P.; Xiang, J. Effect of Radix Salviae Miltiorrhizae on EAA and IAA during cerebral ischemia in gerbils: a microdialysis study. J. Tradit. Chin. Med., 1994, 14(1), 45-50.
197. Kuang, P.; Tao, Y.; Tian, Y. Radix Salviae Miltiorrhizae treatment results in decreased lipid peroxidation in reperfusion injury. J. Trad. Chin. Med., 1996, 16(2), 138-142.
198. Liu, G.; Zhang, T.; Wang, B.; Wang, Y. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem. Pharmacol., 1992, 43(2), 147-152.
199. Zhao, B.; Jiang, W.; Zhao, Y.; Hou, J.; Xin, W. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem. Mol. Biol. Int., 1996, 38(6), 1171-1182.
200. Weng, X.C.; Gordon, M.H. Antioxidant activity of quinines extracted from Tanshen (Salvia miltiorrhiza Bunge). J. Agric. Food Chem., 1992, 40, 1331-1336.
201. Zhang, K.; Bao, Y.; Wu, P.; Rosen, R.T.; Ho, C. Anti-oxidative components of tanshen (Salvia miltiorrhiza Bung). J. Agric. Food Chem., 1990, 38, 1194-1197.
202. Du, G.H.; Qiu, Y.; Zhang, J.T. Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice. J. Asian Nat. Prod. Res., 2000, 2(2), 145-152.
203. Guanhua, D.; Juntian, Z. Protective effects of salvianolic acid A against impairment of memory induced by cerebral ischemiareperfusion in mice. Chin. Med. J. (Engl), 1997, 110(1), 65-68.
204. Huang, Y.S.; Zhang, J.T. Antioxidant effect of three water-soluble components isolated from Salvia miltiorrhiza in vivo. Acta Pharmacol. Sin., 1992, 27(2), 96-100.
205. Kang, H.S.; Chung, H.Y.; Jung, J.H.; Kang, S.S.; Choi, J.S. Antioxidant effect of Salvia miltiorrhiza. Arch. Pharm. Res., 1997, 20(5), 496-500.
206. Chang, H.M.; Chui, K.Y.; Tan, F.W.L.; Yang, Y.; Zhong, Z.P. Structure-activity relationship of miltirone, an active benzodiazepine receptor ligand isolated from Salvia miltiorrhiza Bunge (Danshen). J. Med. Chem., 1991, 34, 1675-1692.
207. Kong, L.D.; Cheng, C.H.; Tan, R.X. Monoamine oxidase inhibitors from rhizome of Copsis chinensis. Planta Med., 2001, 67(1), 74-76.
208. Shigeta, K.; Ootaki, K.; Tatemoto, H.; Nakanishi, T.; Inada, A.; Muto, N. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a Coptidis Rhizoma extract and protoberberine alkaloids. Biosci. Biotechnol. Biochem., 2002, 66(11), 2491-2494.
209. Abe, K.; Saito, H. Effects of saffron extract and its constituent crocin on learning behavior and long-term potentiation. Phytother. Res., 2000, 14(3), 149-152.
210. Park, C.H.; Kim, S.; Choi, W.; Lee, Y.; Kim, J.; Kang, S.S.; Sun, Y.H. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia ruraecarpa. Planta Med., 1996, 62, 405-409.
211. Haji, A.; Momose, Y.; Takeda, R.; Nakanishi, S. Increased feline cerebral blood flow induced by dehydroevodiamine hydrochloride from Evodia rutaecarpa. J. Nat. Prod., 1994, 57(3), 387-389.
212. Nguyen, T.T.H.; Cho, S.O.; Ban, J.Y.; Kim, J.Y.; Ju, H.S.; Koh, S.B.; Song, K-S.; Seong, Y.H. Neuroprotective effect of sanguisorbae radix against oxidative stree-induced brain damage: in vitro and in vivo. Biol. Pharm. Bull., 2008, 31(11), 2028-2035.
213. Yokozawa, T.; Chen, C.P.; Tanaka, T. Direct scavenging of nitric oxide by traditional crude drugs. Phytomedicine, 2000, 6, 453-463.
214. Yokozawa, T.; Chen, C.P.; Tanaka, T.; Kitani, K. Effects of sanguiin H-6, a component of Sanguisorbae Radix, on lipopolysaccharide-stimulated nitric oxide production. Biochem. Pharmacol., 2002, 63, 853-858.
215. Yokozawa, T.; Chen, C.P.; Tanaka, T.; Kitani, K. A study on the nitric oxide production-suppressing activity of Sanguisorbae Radix components. Biol. Pharm. Bull., 2000, 23, 717-722.
216. Mandel, S.A.; Avramovich-Tirosh, Y.; Reznichencko, L.; Zheng, H.; Weinreb, O.; Amit, T.; Youdim, M.B. Multifunctional activities of green tea catechins in neuroprotection. Neurosignals, 2005, 14, 46-60.
217. Yazawa, K.; Kihara, T.; Shen, H.; Shimmyo, Y.; Niidome, T.; Sugimoto, H. Distinct mechanisms underlie distinct polyphenolinduced neuroprotection. FEBSLett. 2006, 580, 6623-6628.
218. Rezai-Zadeh, K.; Shytle, R.D.; Bai, Y.; Tian, J.; Hou, H.; Mori, T.; Zeng, J.; Obregon, D.; Town, T.; Tan, J. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease β-amyloid production. J. Cell. Mol. Med., 2009, 13, 574-588.
219. Giunta, B.; Fernandez, F.; Nikolic, W.V.; Obregon, D.; Rrapo, E.; Town, T.; Tan, J. Inflammaging as a prodrome to Alzheimer's disease. J. Neuroinflammation, 2008, 5, 51.
220. Rocha-González, H.I.; Ambriz-Tututi, M.; Granados-Soto, V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci. Ther., 2008, 14, 234-247.
221. Nonomura, S.; Kanagawa, H.; Makimoto, A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi, 1963, 83, 983-988.
222. Tokusoglu, O.; Unal, M.K.; Yemis, F. Determination of the phytoalexin resveratrol (3,5,4'-trihydroxystilbene) in peanuts and pistachios by high-performance liquid chromatographic diode array (HPLC-DAD) and gas chromatography-mass spectrometry (CGMS). J. Agric. Food Chem., 2005, 53, 5003-5009.
223. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
224. Ribeiro de Lima, M.T.; Waffo-Téguo, P.; Teissedre, P.L.; Pujolas, A.; Vercauteren, J.; Cabanis, J.C.; Mérillon, J.M. Determination of stilbenes (trans-astrigin, cis- and trans-piceid, and cis- and transresveratrol) in Portuguese wines. J. Agric. Food Chem., 1999, 47, 2666-2670.
225. Frémont, L. Biological effects of resveratrol. Life Sci., 2000, 66, 663-673.
226. Granados-Soto, V. Pleiotropic effects of resveratrol. Drug News Perspect., 2003, 16, 299-307.
227. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur. J. Pharmacol., 2006, 545, 51-64.
228. Orgogozo, J.M.; Dartigues, J.F.; Lafont, S.; Letenneur, L.; Commenges, D.; Salamon, R.; Renaud, S.; Breteler, M.B. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev. Neurol. (Paris), 1997, 153, 185-192.
229. Wang, J.; Ho, L.; Zhao, Z.; Seror, I.; Humala, N.; Dickstein, D.L.; Thiyagarajan, M.; Percival, S.S.; Talcott, S.T.; Pasinetti, G.M. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J., 2006, 20, 2313-2320.
230. Jang, J.H.; Surh, Y.J. Protective effect of resveratrol on betaamyloid-induced oxidative PC12 cell death. Free Radic.Biol. Med., 2003, 34, 1100-1110.
231. Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; Puigserver, P.; Sinclair, D.A.; Tsai, L-H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J., 2007, 26, 3169-3179.
232. Rivière, C.; Richard, T.; Quentin, L.; Krisa, S.; Mérillon, J.M.; Monti, J.P. Inhibitory activity of stilbenes on Alzheimer's betaamyloid fibrils in vitro. Bioorg. Med. Chem., 2007, 15, 1160-1167.
233. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearence of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem., 2005, 280, 37377-37382.
234. Miloso, M.; Bertelli, A.A.; Nicolini, G.; Tredici, G. Resveratrolinduced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 1999, 264, 141-144.
235. Han, Y.S.; Zheng, W.H.; Bastianetto, S.; Chabot, J.G.; Quirion, R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C. Br. J. Pharmacol., 2004, 141, 997-1005.
236. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid -beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280, 40364-40374.
237. Kim, Y.A.; Lim, S.Y.; Rhee, S.H.; Park, K.Y.; Kim, C.H.; Choi, B.T.; Lee, S.J.; Park, Y.M.; Choi, Y.H. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int. J. Mol. Med., 2006, 17, 1069-1075.
238. Han, Y.S.; Zheng, W.H.; Bastinetto, S.; Chabot, J.G.; Quirion, R. Neuroprotective effects of resveratrol against beta-amyloidinduced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Brit. Pharm. Soc., 2004, 141, 997-1005.
239. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke L., Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NK-kappaB signaling. J. Biol. Chem., 2005, 280, 40364-40374.
240. Anekonda, T.S. Resveratrol - a boon for treating Alzheimer's disease? Brain Res. Ver., 2006, 52, 316-326.
241. Gelinas, S.; Martinoli, M.G. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxity in neuronal PC12 cells. J. Neurosci. Res., 2002, 70, 90-96.
242. Conte, A.; Pellegrini, S.; Tagliazucchi, D. Effect of resveratrol and catechin on PC12 tyrosine kinase activities and their synergistic protection from beta-amyloid toxicity. Drugs Exp. Clin. Res., 2003, 29, 243-255.
243. Conte, A.; Pellegrini, S.; Tagliazucchi, D. Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin. Brain Res. Bull., 2003, 62, 29-38.
244. Ono, K.; Naiki, H.; Yamada, M. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of betaamyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr. Pharm. Design, 2006, 12, 4357-4375.
245. Ono, K.; Yamada, M. Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem., 2006, 97, 105-115.
246. Bi, X.L.; Yang, J.Y.; Dong, Y.X.; Wang, J.M.; Cui, Y.H.; Ikeshima, T.; Zhao, Y.Q.; Wu, C.F. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int. Immunopharmacol., 2005, 5, 185-193.
247. Kim, Y.A.; Kim, G.Y.; Park, K.Y.; Choi, Y.H. Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharideactivated C6 microglia. J. Med. Food, 2007, 10, 218-224.
248. Gao, D.; Zhang, X.; Jiang, X.; Peng, Y.; Huang, W.; Cheng, G.; Song, L. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci., 2007, 78, 2564-2570.
249. Ates, O.; Cayli, S.; Altinaz, E.; Gurses, I.; Yucel, N.; Sener, M.; Kocak, A.; Yologlu, S. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol. Cell Biochem., 2007, 294, 137-144.
250. Inoue, H.; Jiang, X.F.; Katayama, T.; Osada, S.; Umesono, K.; Namura, S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci.Lett. 2003, 352, 203-206.
251. Gao, Z.B.; Hu, G.Y. Trans-resveratrol, a red wine ingredient, inhibits voltage-activated potassium currents in rat hippocampal neurons. Brain Res., 2005, 1056, 68-75.
252. Sinha, K.; Chaudhary, G.; Gupta, Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci., 2002, 71, 655-665.
253. Wang, Q.; Xu, J.; Rottinghaus G.E.; Simonyi, A.; Lubahn, D.; Sun, G.Y.; Sun, A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958, 439-447.
254. Kumar, P.; Padi, S.S.; Naidu, P.S.; Kumar, A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: Possible neuroprotective mechanism. Behav. Pharmacol., 2006, 17, 485-492.
255. Kumar, A.; Naidu, P.S.; Seghal, N.; Padi, S.S. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology, 2007, 37, 17-26.
256. Stolk, J.; Hiltermann, T.J.; Dijkman, J.H.; Verhoeven, A.J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Resp. Cell Mol. Biol., 1994, 11, 95-102.
257. Infanger, D.W.; Sharma, R.V.; Davisson, R.L. NADPH oxidases of the brain: Distribution, regulation, and function. Antioxid. Redox Signal., 2006, 8, 1583-1596.
258. Dringen, R. Oxidative and antioxidative potential of brain microglial cells. Antioxid. Redox Signal., 2005, 7, 1223-1233.
259. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans., 2007, 35, 1119-1121.
260. Barbieri, S.S.; Cavalca, V.; Eligini, S.; Brambilla, M.; Caían, A.; Tremoli, E.; Colli, S. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redoxdependent mechanisms. Free Rad. Biol. Med., 2004, 37, 156-165.
261. Li, M.; Pisalyaput, K.; Galvan, M.; Tenner, A.J. Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for argumentation of beta-amyloid-induced microglia-mediated neurotoxicity. J. Neurochem., 2004, 91, 623-633.
262. Jekabsone, A.; Mander, P.K.; Tickler, A.; Sharpe, M.; Brown, G.C. Fibrillar beta-amyloid peptide Abeta1-40 activities microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J. Neuroinflammation, 2006, 3, 24.
263. Shibata, H.; Katsuki, H.; Okawara, M.; Kume, T.; Akaike, A. C-Jun Nterminal kinase inhibition and alpha-tocopherol protect midbrain dopaminergic neurons from interferon-gamma/lipopolysaccharideinduced injury without affecting nitric oxide production. J. Neurosci. Res., 2006, 83, 102-109.
264. Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M.B. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: Implications for neurodegenerative diseases. J. Neurochem., 2004, 88, 1555-1569.
265. Mandel, S.; Youdim, M.B. Catechin polyphenols: Neurodegeneration and neuroprotection in neurodegenerative diseases. Free Rad. Biol. Med., 2004, 37, 304-317.
266. Rezai-Zadeh, K.; Shytle, D.; Sun, N.; Mori, T.; Hou, H.; Jeanniton, D.; Ehrhart, J.; Townsend, K.; Zeng, J.; Morgan, D.; Hardy J.; Town, T.; Tan, J. Green tea Epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci., 2005, 25, 8807-8814.
267. Weinreb, O.; Amit, T.; Youdim, M.B. The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate. Arch. Biochem. Biophys., 2008, 476, 152-160.
268. Obregon, D.F.; Rezai-Zadeh, K.; Bai, Y.; Sun, N.; Hou, H.; Ehrhart, J.; Zeng, J.; Mori, T.; Arendash, G.W.; Shytle, D.; Town, T.; Tan, J. ADAM10 activation is required for green tea (-)-Epigallocatechin-3-gallate-induced α-secretase cleavage of amyloid precursor protein. J. Biol. Chem., 2006, 281, 16419-16427.
269. Miwa, H.; Iijima, M.; Tanaka, S.; Mizuno, Y. Generalized convulsions after consuming a large amount of ginkgo nuts. Epilepsia, 2001, 42, 280-281.
270. Fessenden, J.M.; Wittenborn, W.; Clarke, L. Ginkgo biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am. Surg., 2001, 67, 33-35.
271. Galluzi, S.; Zanetti, O.; Binetti, G.; Trabucchi, M.; Frisoni, G.B. Coma in a patient with Alzheimer's disease taking low dose trazodone and Ginkgo biloba. J. Neurol Neurosurg. Psychiatry, 2000, 68, 679-680.
272. DeKosky, S.T.; Williamson, J.D.; Fitzpatrick, A.L.; Kronmal, R.A.; Ives, D.G.; Saxton, J.A.; Lopez, O.L.; Burke, G.; Carlson, M.C.; Fried, L.P.; Kuller, L.H.; Robbins, J.A.; Tracy, R.P.; Woolard, N.F.; Dunn, L.; Snitz, B.E.; Nahin, R.L.; Furberg, C.D. Ginkgo biloba for prevention of dementia: a randomized controlled trial. J. Am. Med. Assoc., 2008, 300, 2253-2262.
273. van Dongen, M.C.; van Rossum, E.; Kessels, A.G.; Sielhorst H.J.; Knipschild P.G. The efficacy of Ginkgo for elderly people with dementia and aged-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc., 2000, 48, 1183-1194.
274. Schneider, L.S.; DeKosky, S.T.; Farlow, M.R.; Tariot, P.N.; Hoerr, R.; Kieser, M. A randomized, doublé-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res., 2005, 2, 541-551.
275. Neugroschl, J.; Sano, M. Current treatment and recent clinical research in Alzheimer's disease. Mount Sinai J. Med., 2010, 77, 3-16.
276. Schneider, L.S. Ginkgo biloba extract and preventing Alzheimer's disease. J. Am. Med. Assoc., 2008, 300, 2306-2308.
277. Freund-Levi, Y.; Eriksdotter-Jonhagen, M.; Cederholm, T.; Basun, H.; Faxén-Irving, G.; Garlind, A.; Vedin, I.; Vessby, B.; Wahlund, L-O.; Palmblad, J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer's disease: OmegAD study: a randomized douybleblind trial. Arch. Neurol., 2006, 63, 1402-1408.
278. Results from Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline, available at: http://www.alz.org/icad/2010_release_071209_1am_b.asp. [Accessed January 2010].
279. Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00678431. [Accessed February 2010].
280. Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease. Available at: http://clinicaltrials.gov/ct2/show/NCT01001637 [Acessed December 2009].